Camille Le Gall (Camille M Le Gall)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 9

Top Topics

Pseudomonas Aeruginosa

Regulatory T Cells

Top Venues

Research square

Nature communications

Molecular pharmaceutics

Bioconjugate chemistry

This page only lists publications with an associated author ORCID identifier.

Publications

Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Hidde L Ploegh, Xin Liu, Camille Le Gall, Ryan Alexander, Ella Borgman, Thomas Balligand
Bi-specific antibody engagers for cancer immunotherapy. Research square (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Hidde L Ploegh, Xin Liu, Camille Le Gall, Ryan Alexander, Ella Borgman, Thomas Balligand
Bi-specific antibody engagers for cancer immunotherapy. Research square (2024)
Thomas Eden, Alessa Z Schaffrath, Janusz Wesolowski, Tobias Stähler, Natalie Tode, Nathalie Richter, Waldemar Schäfer, Julia Hambach, Irm Hermans-Borgmeyer, Jannis Woens, Camille Le Gall, Sabrina Wendler, Christian Linke-Winnebeck, Martina Stobbe, Iwona Budnicki, Amelie Wanney, Yannic Heitz, Lena Schimmelpfennig, Laura Schweitzer, Dennis Zimmer, Erik Stahl, Fabienne Seyfried, Anna J Gebhardt, Lynn Dieckow, Kristoffer Riecken, Boris Fehse, Peter Bannas, Tim Magnus, Martijn Verdoes, Carl G Figdor, Klaus F Hartlepp, Hubertus Schleer, Jonas Füner, Nicola M Tomas, Friedrich Haag, Björn Rissiek, Anna M Mann, Stephan Menzel, Friedrich Nolte
Generation of nanobodies from transgenic 'LamaMice' lacking an endogenous immunoglobulin repertoire. Nature communications 15 (1) (2024)
Hidde L Ploegh, Xin Liu, Camille Le Gall, Ryan Alexander, Ella Borgman, Thomas Balligand
Bi-specific antibody engagers for cancer immunotherapy. Research square (2024)
Zacharias Wijfjes, Floris J van Dalen, Camille Le Gall, Martijn Verdoes
Controlling Antigen Fate in Therapeutic Cancer Vaccines by Targeting Dendritic Cell Receptors. Molecular pharmaceutics (2023)
Camille Le Gall, Anna Cammarata, Lukas de Haas, Iván Ramos-Tomillero, Jorge Cuenca-Escalona, Kayleigh Schouren, Zacharias Wijfjes, Anouk M D Becker, Johanna Bödder, Yusuf Dölen, Ingrid Jolanda M De Vries, Carl G Figdor, Georgina Flórez-Grau, Martijn Verdoes
Efficient targeting of NY-ESO-1 tumor antigen to human cDC1s by lymphotactin results in cross-presentation and antigen-specific T cell expansion. Journal for immunotherapy of cancer 10 (4) (2022)
Camille Le Gall, Johan M S van der Schoot, Iván Ramos-Tomillero, Melek Parlak Khalily, Floris J van Dalen, Zacharias Wijfjes, Liyan Smeding, Duco van Dalen, Anna Cammarata, Kimberly M Bonger, Carl G Figdor, Ferenc A Scheeren, Martijn Verdoes
Dual Site-Specific Chemoenzymatic Antibody Fragment Conjugation Using CRISPR-Based Hybridoma Engineering. Bioconjugate chemistry 32 (2) (2021)